Looking backward to move forward: Early detection of neurodegenerative disorders

被引:292
作者
Dekosky, ST [1 ]
Marek, K
机构
[1] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA
[2] Univ Pittsburgh, Sch Med, Alzheimer Dis Res Ctr, Pittsburgh, PA 15261 USA
[3] Inst Neurodegenerat Disorders, New Haven, CT USA
关键词
D O I
10.1126/science.1090349
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Early detection of neurodegenerative disorders would provide clues to the underlying pathobiology of these diseases and would enable more effective diagnosis and treatment of patients. Recent advances in molecular neuroscience have begun to provide the tools to detect diseases like Alzheimer's disease, Parkinson's disease, and others early in their course and potentially even before the development of clinical manifestations of disease. These genetic, imaging, clinical, and biochemical tools are being validated in a number of studies. Early detection of these slowly progressive diseases offers the promise of presymptomatic diagnosis and, ultimately, of disease-modifying medications for use early in disease and during the presymptomatic period.
引用
收藏
页码:830 / 834
页数:5
相关论文
共 83 条
[1]  
[Anonymous], 2003, MILD COGNITIVE IMPAI
[2]   Serum creatinine levels correlate with plasma amyloid β protein [J].
Arvanitakis, Z ;
Lucas, JA ;
Younkin, LH ;
Younkin, SG ;
Graff-Radford, NR .
ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 2002, 16 (03) :187-190
[3]   Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework [J].
Atkinson, AJ ;
Colburn, WA ;
DeGruttola, VG ;
DeMets, DL ;
Downing, GJ ;
Hoth, DF ;
Oates, JA ;
Peck, CC ;
Schooley, RT ;
Spilker, BA ;
Woodcock, J ;
Zeger, SL .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) :89-95
[4]   Detection of neuritic plaques in Alzheimer's disease by magnetic resonance microscopy [J].
Benveniste, H ;
Einstein, G ;
Kim, KR ;
Hulette, C ;
Johnson, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (24) :14079-14084
[5]   Subclinical dopaminergic dysfunction in asymptomatic Parkinson's disease patients' relatives with a decreased sense of smell [J].
Berendse, HW ;
Booij, J ;
Francot, CMJE ;
Bergmans, PLM ;
Hijman, R ;
Stoof, JC ;
Wolters, EC .
ANNALS OF NEUROLOGY, 2001, 50 (01) :34-41
[6]   Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease [J].
Bezard, E ;
Dovero, S ;
Prunier, C ;
Ravenscroft, P ;
Chalon, S ;
Guilloteau, D ;
Crossman, AR ;
Bioulac, B ;
Brotchie, JM ;
Gross, CE .
JOURNAL OF NEUROSCIENCE, 2001, 21 (17) :6853-6861
[7]   Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset [J].
Brookmeyer, R ;
Gray, S ;
Kawas, C .
AMERICAN JOURNAL OF PUBLIC HEALTH, 1998, 88 (09) :1337-1342
[8]  
Brooks DJ, 2000, ADV NEUROL, V82, P209
[9]   In-vivo measurement of activated microglia in dementia [J].
Cagnin, A ;
Brooks, DJ ;
Kennedy, AM ;
Gunn, RN ;
Myers, R ;
Turkheimer, FE ;
Jones, T ;
Banati, RB .
LANCET, 2001, 358 (9280) :461-467
[10]   Cognitive tests that best discriminate between presymptomatic AD and those who remain nondemented [J].
Chen, P ;
Ratcliff, G ;
Belle, SH ;
Cauley, JA ;
DeKosky, ST ;
Ganguli, M .
NEUROLOGY, 2000, 55 (12) :1847-1853